Ferdinand E. Massari, M.D.

Ferd Massari is CEO of  ProTgen and works in the company’s headquarters in mid-town Manhattan. Prior to ProTgen, Ferd was a C-suite executive at various early-stage companies including President of R&D at Kintai Therapeutics, a company created out of Flagship Pioneering and Chief Medical Officer at various companies such as Deep Genomics and Coley Pharmaceuticals.   Prior to his work over the last 14 years in the entrepreneurial, startup space, Ferd served as  VP and Global Head of Clinical and Medical Affairs in the rare diseases division of Shire, Vice President of Worldwide Medical Affairs at Pfizer, Vice President of Clinical Research at Pharmacia, and Director of Infectious Diseases at Merck Research Laboratories developing treatments for HIV infection.

Ferd trained in internal medicine after obtaining his medical degree at Jefferson Medical College in Philadelphia under an NHSC scholarship. He received his Allergy & Immunology training at the National Institute of Allergy and Infectious Diseases in the laboratory of the Director, Dr. Anthony S. Fauci, under a NRSA scholarship researching the immunopathogenesis of HIV.